Shares in Oxford GlycoSciences plummeted after a City analyst recommended investors to sell, writes Maggie Hartford.
Chief executive Michael Kranda said the recommendation was based on a letter to medical journal The Lancet casting doubt on clinical trial results of OGS's potential treatment for Gaucher's disease, a rare inherited condition.
Company scientists had refuted the letter writer's points, said Mr Kranda, and independent experts had concluded that the treatment should be investigated further. "I am sure that the share price will go up again," he said.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article